The E3 ubiquitin ligase adaptor speckle-type POZ protein (SPOP) is frequently dysregulated in prostate adenocarcinoma (PC), via either somatic mutations or mRNA downregulation, suggesting an important tumour suppressor function. To examine its physiologic role in the prostate epithelium in vivo, we generated mice with prostate-specific biallelic ablation of Spop. These mice exhibited increased prostate mass, prostate epithelial cell proliferation, and expression of c-MYC protein compared to littermate controls, and eventually developed prostatic intraepithelial neoplasia (PIN). We found that SPOP WT can physically interact with c-MYC protein and, upon exogenous expression in vitro, can promote c-MYC ubiquitination and degradation. This effect was attenuated in PC cells by introducing PC-associated SPOP mutants or upon knockdown of SPOP via short-hairpin-RNA, suggesting that SPOP inactivation directly increases c-MYC protein levels. Gene Set Enrichment Analysis revealed enrichment of Myc-induced genes in transcriptomic signatures associated with SPOP MT . Likewise, we observed strong inverse correlation between c-MYC activity and SPOP mRNA levels in two independent PC patient cohorts. The core SPOP MT ;MYC High transcriptomic response, defined by the overlap between the SPOP MT and c-MYC transcriptomic programmes, was also associated with inferior clinical outcome in human PCs. Finally, the organoid-forming capacity of Spop-null murine prostate cells was more sensitive to c-MYC inhibition than that of Spop-WT cells, suggesting that c-MYC upregulation functionally contributes to the proliferative phenotype of Spop knockout prostates. Taken together, our data highlight SPOP as an important regulator of luminal epithelial cell proliferation and c-MYC expression in prostate physiology, identify c-MYC as a novel bona fide SPOP substrate, and help explain the frequent inactivation of SPOP in human PC. We propose SPOP MT -induced stabilization of c-MYC protein as a novel mechanism that can increase total c-MYC levels in PC cells, in addition to amplification of c-MYC locus.
INTRODUCTION
Whole exome sequencing studies have identified the Cullin-3-based ubiquitin (Ub) ligase adaptor speckle-type POZ protein (SPOP) as one of the genes that is most frequently affected by non-synonymous somatic point mutations in primary prostate adenocarcinoma (PC or PRAD). [1] [2] [3] [4] Mutation of conserved residues in the SPOP substrate-binding pocket altering its substrate specificity [5] [6] [7] is an early event in prostate carcinogenesis, 2, 8 suggesting that they are an important oncogenic driver. The list of known SPOP substrates has rapidly expanded and currently includes the death domain-associated protein Daxx, 9 the phosphatase Puc, 7 the transcriptional regulators Ci/Gli, 7, 10 MacroH2A, 7 and DDIT3/CHOP, 11 the desumoylase SENP7, 12 CDC20, 13 DEK 14 and ERG, 15, 16 the androgen receptor 6, 17 and its coactivators Steroid Receptor Coactivator (SRC)-3 5, 14, 18 and TRIM24. 14, 19 Previously, we demonstrated that PC-associated SPOP mutants are unable to interact with androgen receptor or SRC-3, 5, 6 leading to stabilization of androgen receptor and SRC-3 and an increase in androgen receptor-axis transcriptional output, thus providing a possible mechanism to explain their role in PC pathophysiology. Indeed, the Cancer Genome Atlas (TCGA) analysis of 333 primary prostate carcinomas has confirmed that SPOP MT tumours have the highest levels of androgen receptorinduced transcripts. 4 However, the physiological role of endogenous SPOP WT in the prostate epithelium remains to be fully elucidated. Towards this goal, we utilized two Spop (also known as Pcif1) KO mouse models: a whole-body hemizygous model and a conditional prostatespecific biallelic ablation model. Ablation of one or two Spop alleles resulted in increased prostate mass, cell proliferation, and higher expression of androgen receptor and c-MYC proteins in the mouse prostate luminal epithelial cells, compared to respective controls. Ablation of both Spop alleles in the prostate resulted in hyperplasia, dysplasia and nuclear atypia in the luminal epithelium, which, by 38 weeks of age, developed into prostatic intraepithelial neoplasia (PIN). Our studies further revealed c-MYC as a novel bona fide SPOP substrate. SPOP WT promotes c-MYC ubiquitination and degradation and this capacity is attenuated in the PC-associated SPOP mutants. Bioinformatics analysis of transcriptomic signatures associated with SPOP MT programme, was prognostic of inferior clinical outcome when applied to a human PC dataset. Taken together, our data highlight SPOP as an important regulator of luminal cell proliferation and c-Myc expression in the normal prostate epithelium and help explain why SPOP is frequently inactivated in human PC.
RESULTS
Prostate-specific biallelic ablation of Spop increases prostate mass and luminal epithelial cell proliferation Surveys of numerous clinical PC datasets unequivocally demonstrate that Spop mRNA levels are frequently decreased in primary and hormone-naïve metastatic PC compared to normal prostate tissue 2, 20 and (Supplementary Figure 1) . This observation led us to examine the exact function of SPOP WT in normal prostate physiology. As homozygous Spop deletion results in neonatal lethality (between E18.5 and P1), 21 we generated a prostatespecific biallelic knockout mouse model (Supplementary Figure 2) . ;PBCre( − ) mice to determine the effects of prolonged absence of Spop on the mouse prostate. We found that biallelic ablation of Spop resulted in increased cellularity, hyperplasia, nuclear atypia and dysplasia in the luminal epithelium developing into PIN in the dorsolateral prostate and ventral prostate (Figures 2a-c) . These cells stained positive for the luminal marker, cytokeratin-8 ( Supplementary Figures 5A-B) . Similar to the observations in the 8-week-old mice, 38-week-old Spop fl/fl ;PBCre(+) mice continued to have significantly increased prostate mass compared to their Spop fl/fl ;PBCre( − ) littermates (P-value o0.001, Figure 2d ), despite no difference in overall body mass (Supplementary Figure 3B) . ;PBCre(+), we found that disruption of one Spop allele also resulted in increased mouse prostate mass (Po0.05, Supplementary Figure 6A ) at 8-weeks of age compared to wildtype mice, without any significant difference in overall body mass (Supplementary Figure 6B) . Immunohistochemical analysis demonstrated that Ki67 expression was also higher (P-valueo0.02, Supplementary Figure 6C ;PBCre(+) (n = 3) and analysed by immunoblot for SPOP, androgen receptor, c-Myc and β-ACTIN.
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mice. In agreement with our prior results 6 and current finding in prostate-specific biallelic knockout model, we observed an increase in both androgen receptor and c-MYC expression in Spop heterozygote prostates compared to wildtype littermates (Supplementary Figure 7) .
Biallelic loss of Spop results in an increase in TUNEL-positive cells in mouse prostate tissue and decrease in organoid size Stemming from our hypothesis that SPOP plays a critical role in the prostate epithelium, we next examined whether SPOP can regulate cell death. Indeed, we found an increase in the presence of TUNEL-positive cells in both prostate tissue and organoids generated from 8-week-old Spop fl/fl ;PBCre(+) mice ( Supplementary  Figures 8 and 9 ). We found that organoids from 8-week-old Spop fl/fl ;PBCre(+) mice were significantly smaller than those from control littermates (Supplementary Figure 9) .
In order to further understand the fate of the Spop knockout cells, we used the Cre-recombinase enzyme to track the fate of SPOP KO cells. Immunohistochemical staining revealed that prostate epithelium of 8-week-old mice had high expression of Cre-recombinase protein (in the ventral and dorsolateral prostate), while Cre-negative littermate controls had no staining, as expected (Supplementary Figure 10) . Interestingly, the population of Cre-positive cells decreased in the prostate of older Spop fl/fl ; PBCre(+) mice while it remained high in 12-month-old Spop WT ; PBCre(+) mice, suggesting that the reduction in the population of Cre-positive cells in the knockout mice was not due to an agerelated decrease in testosterone and/or activity of probasin promoter (Supplementary Figure 10) . 28 In all three analyses, we found that the core MYC High ;SPOP MT ; transcriptional programme was strongly associated with inferior clinical outcomes (decreased BCR-free survival, P-value o 0.02 by log-rank test, Figures 3d-f) in human PCs, while the individual SPOP MT and MYC High transcriptional programmes did not reach statistical significance (Supplementary Figure 11 , an observation that is in agreement with the fact that SPOP MT status, as a single biomarker, is not associated with poor clinical outcomes in PC 27 ). Thus, we now propose that the shared core SPOP MT 
;Myc
High transcriptional programme is reflective of a critical cooperation between SPOP and c-Myc that is used to drive clinically aggressive PC. Over-representation analysis of pathways and processes highlighted that the combined signature SPOP MT (TCGA);Myc High enriched for key cell cyclerelated cellular pathways (Supplementary Figure 12) .
Lastly, we computed MYC activity scores by applying the abovementioned gene signatures to the Taylor et al and TCGA-PRAD patient datasets. We found significant inverse correlation between SPOP mRNA level and MYC activity, suggesting that SPOP suppresses MYC activity in human PC ( Figure 4 ).
SPOP directly binds the c-Myc protein, resulting in ubiquitination and degradation of c-Myc Our finding of increased androgen receptor protein levels in mouse prostates with Spop ablation is in agreement with our prior finding that androgen receptor is a bona fide SPOP substrate. 6 However, the impact of SPOP on c-MYC turnover has not been previously reported. Our in vivo observation of increased c-Myc 28 for each PC specimen we calculated the signature activity score, as described in Methods. All three SPOP MT ;MYC High core geneset have significantly shorter BCR-free survival in the upper 10% compared to the bottom 90% (log-rank test, Po0.02).
Regulation of prostate growth and c-Myc expression by SPOP C Geng et al protein levels in Spop-ablated mouse prostates, along with identification of a critical, shared core transcriptional programme between these two important PC drivers, led us to hypothesize that c-MYC is also an SPOP substrate. Thus, we next examined the expression of c-MYC upon knockdown of SPOP via short-hairpin RNA using a doxycycline inducible system. We found that inhibition of SPOP in PC cell lines resulted in an increase in c-MYC protein in PC cell lines (Figure 5a and Supplementary Figure 13 ). We next utilized previously generated LNCaP cells expressing SPOP WT or PC-associated substrate binding pocket mutants (SPOP-F102C and SPOP-F133V) under the control of a tetracycline-inducible promoter and found that SPOP WT , but not its PC-associated mutants, caused significant depletion of c-MYC protein (Figure 5b ).
To examine whether SPOP physically associates with c-MYC in PC cells, we immunoprecipitated SPOP from the lysates of LNCaP PC cells. We found that endogenous SPOP (WT) can physically associate with c-Myc in human PC cells (Figure 5c ). We next co-expressed c-Myc and SPOP WT or the PC-associated substrate binding pocket mutants, SPOP F102C and SPOP F133V , in 293T cells and observed that SPOP WT could effectively co-immunoprecipitate with c-Myc. This capacity was attenuated by its PC-associated substrate binding pocket mutations (Figure 5c ). In agreement, in an ubiquitination assay, SPOP WT , but not the PC-associated mutant SPOP F102C , promoted ubiquitination of c-Myc (Figure 6a ). We next examined whether the interaction between c-Myc and SPOP WT is due to SPOP directly binding to a specific sequence on c-Myc. A serine/threonine-rich SPOP Binding Consensus motif (SBC) has been previously defined. 7 Examination of the c-Myc protein sequence identified two such putative SBC sequences (SBC1: aa 185 VCSTS 189 and SBC2: aa 261 PTTSS 265). We generated expression vectors for c-Myc mutated at either of these In addition, ΔSBC1 c-Myc was largely insensitive to SPOPpromoted ubiquitination. ΔSBC2 c-Myc was also protected (albeit partially) from SPOP-promoted ubiquitination (Figure 6c ), in agreement with our finding of some weak persistent binding of SPOP WT to ΔSBC2 c-Myc. These data support the functional significance of the direct interaction between SPOP and c-Myc and identify the c-Myc SBC1 sequence as the dominant mediator of this binding (although a role for SBC2 is also likely, possibly in cooperation). In agreement, ΔSBC1 c-Myc was completely protected from SPOP-promoted degradation (Figure 6d ).
Post-translational regulation of c-Myc turnover by SPOP WT Our finding that SPOP WT can directly bind the WT c-Myc protein and promote its ubiquitination, suggests that SPOP WT promotes post-translational degradation of c-Myc, similar to its effects on several other of its substrates. 5, 6, 10, 14, 17 In support of a posttranslational effect of SPOP WT on c-Myc turnover, we also found that upon co-transfection of SPOP and c-Myc expression vectors (that is, conditions where SPOP WT suppresses c-Myc protein levels, Figure 6d ), we did not detect a decrease in mRNA levels of transfected c-Myc (Supplementary Figure 14) .
For further validation, we quantified the half-life of endogenous c-Myc in our PC LNCaP cells expressing SPOP WT upon induction with doxycycline. Using cycloheximide treatment to suppress new protein synthesis, we determined that induction of SPOP WT c-Myc Activity (Generated using GSE37428 Overexpression of cMyc in murine prostate) c-Myc Activity (Generated using GSE51384 cMyc Induction in LNCaP) c-Myc Activity (Generated using Koh et ) is incompatible with postnatal survival. 21 However, we were able to generate mouse embryonic fibroblasts (MEFs) from mice lacking one (Spop − /+ ) or both (Spop − / − ) Spop alleles and from wildtype littermates (Spop +/+ ). Using these MEFs, we found an inverse correlation between Spop and c-Myc protein levels (Figure 7b) , suggesting that the regulation of c-Myc protein levels by SPOP WT is not restricted to prostate cells. MYC levels are tightly regulated by the ubiquitin-proteasome system and multiple ubiquitin ligases have been identified to target Myc as a substrate. [29] [30] [31] [32] [33] [34] [35] [36] [37] Based on this literature, we identified 16 regulators (E3 ligases and their adaptors, including SPOP itself), which have been proposed to regulate cMYC protein stability and thus, alter its function, and examined the mRNA expression levels of these regulators in PC patient datasets (Supplementary Figure 16) . We also examined whether the mRNA levels of these regulators showed any significant correlation with MYC activity in prostate. Like SPOP, we found that the mRNA levels of several other MYC regulators were lower in PC compared to normal tissue and generally showed an inverse correlation with MYC activity in patient datasets (Supplementary Tables 1-6 ). Thus, we conclude that SPOP is one of several regulators that play a critical role in tightly controlling MYC turnover rate in prostate tissue.
Loss of Spop increases sensitivity to Myc inhibition
Finally, we examined the functional significance of the regulation of c-MYC by SPOP in prostate cells. We examined the levels of c-Myc in our organoids generated from whole prostate of Spop Figure 17) . Consequently, we found that the organoids generated from the Spop fl/fl ;PBCre(+) mice were more sensitive to MYC inhibition compared to those generated from control littermates (Figure 7c) , suggesting that the upregulation of MYC protein contributes, at least partly, to the pathophysiology of Spop-null prostate luminal epithelial cells.
DISCUSSION
The frequent presence of SPOP missense mutations and downregulation of its mRNA in PC suggest that SPOP plays an important tumour suppressor role in the normal prostate. We have previously reported that overexpression of SPOP WT decreases proliferation of PC cells in vitro. 5 A similar tumour suppressor role has been proposed for SPOP in gastric cancer, 38 colorectal cancer 39, 40 and in glioma. 41 To date, SPOP deletion has never been observed in PC. We now examined the physiologic role of Spop in the mouse prostate utilizing whole-body heterozygous and prostate-specific biallelic ablation models. We should reiterate that these models were not intended to mimic human SPOP MT PC, where hotspot SPOP mutations always occur in heterozygote fashion (without LOH of the WT allele, thus suggesting that complete loss of SPOP expression and function never happens in human PC), but were rather designed to investigate the role of SPOP in the prostate epithelium. However, as SPOP mRNA levels in many human PCs are suppressed to, on average, half of normal prostate levels, 2 the hemizygous prostates may resemble the SPOP status of a subset of SPOP WT human PCs. For biallelic loss of Spop, a prostate-specific targeting approach was necessary (whole-body complete loss of Spop is incompatible with postnatal survival 21 ). In both models, ablation of Spop resulted in increased prostate mass and luminal epithelial cell proliferation. In the homozygous prostate-specific knockout model, by week 38, the mice developed PIN lesions in the dorsolateral and ventral prostate.
Both models also showed increased expression of androgen receptor and c-MYC protein in the luminal cells. c-Myc is a protooncogene 22 with an established role in PC, [23] [24] [25] [42] [43] [44] [45] [46] [47] [48] [49] [50] including the fact that the MYC locus on 8q24 is frequently amplified in human PC. 46, [51] [52] [53] [54] As c-Myc previously had not received attention as a possible SPOP substrate, we examined further its relationship with SPOP. We found that SPOP well-known FBXW7 [32] [33] [34] and SKP2. [35] [36] [37] We propose SPOP MT -induced stabilization of c-Myc protein as another mechanism that can raise c-MYC levels in PC cells, in addition to c-Myc locus amplification.
Our in vivo findings of c-MYC regulation by SPOP led us to further examine the relationship between c-MYC and SPOP signalling. We found that the transcriptomic footprints associated with SPOP MT in human PC specimens (TCGA cohort 4 ) and in PC cells cultured in vitro 6 both enriched for Myc-induced genes. Moreover, an overlapping, core transcriptomic programme between the SPOP MT and MYC High gene signatures was predictive of inferior clinical outcomes in human PCs, regulating key cellular pathways (primarily cell cycle). Thus, while the SPOP MT status (as a single biomarker) does not appear so far to be associated with clinical outcomes in PC, 55 we now propose that the combined (dys)regulation of the SPOP and Myc pathways can cooperatively drive a clinically aggressive PC programme. In agreement, we found that the organoid-forming capacity of Spop-null prostate cells is significantly more sensitive to MYC inhibition compared to that of SPOP WT cells, suggesting that MYC upregulation functionally contributes to the proliferative phenotype of Spop knockout prostates.
Another interesting observation of our study was the increased presence of TUNEL-positive nuclei in both prostate tissue and in organoids from 8-week-old mice with biallelic loss of Spop. This, along with our observation that the population of Cre-positive cells decreased in Spop fl/fl ;PBCre(+)prostates with time, while remaining high in aging Spop WT ;PBCre(+) counterparts, likely suggest that the complete loss of SPOP may ultimately exert a negative selection pressure on the prostate cell. This dual role of SPOP is consistent with the clinical observation that although SPOP is frequently mutated and its mRNA expression downregulated in prostate cancer, the mutations are always heterozygous and there is always some residual SPOP WT mRNA expression. In other words, while the baseline levels of SPOP in the normal prostate likely exert a tumour suppressor role, and hence, it is favourable for the prostate cancer cell to partially suppress SPOP activity, however, some residual SPOP function remains critical for the survival of the prostate cancer cell.
In conclusion, our study highlights SPOP as an important regulator of cell proliferation and c-Myc expression in the prostate luminal epithelium and contribute to our understanding of its role in prostate physiology. We have identified c-MYC as a novel bona fide SPOP substrate and highlight a critical contribution of SPOP MT as a key partner of c-MYC in transcriptional regulation and clinical outcomes in PC. Collectively, these data help explain why SPOP is so frequently inactivated in human PC (by decreased expression and somatic point mutations).
MATERIALS AND METHODS

Cell culture
Human cells lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA), authenticated by STR profiling and subjected to mycoplasma testing, and passaged for fewer than 6 months. LNCaP cells harbouring WT or mutant (F102C or F133V) SPOP under doxycycline-inducible promoter were described previously 5, 6 and were maintained in RPMI1640 medium with 10% tetracycline-free FBS (Atlanta Biotech Inc., Atlanta, GA, USA) and 300 μg/ml G-418 (Invitrogen, Carlsbad, CA, USA). LNCaP and 22Rv1 harbouring doxycycline-inducible shSPOP expression constructs, LNCaP-shSPOP-A, LNCaP-shSPOP-B, LNCaP-shGFP, 22Rv1-shSPOP-A, 22Rv1-shSPOP-B or 22Rv1-shGFP cell lines were maintained in RPMI1640 plus 10% Tet-tested FBS (Atlanta Biotech) and 0.5 μg/ ml puromycin (Invitrogen).
Reagents and antibodies
The antibodies used in this study were mouse-monoclonal anti-FLAG-M2 (#F1804), mouse anti-β-Actin (#A2228), mouse anti-FLAG-HRP (#A8592), anti-rat IgG-HRP (#A9037 Sigma All animal experiments were performed under a protocol approved by the BCM IACUC. . We have documented that these heterozygote (Spop +/-) prostates express approximately half the amount of Spop mRNA compared to WT mice, 6 which recapitulates its suppressed expression levels in SPOP WT hormone-naïve metastatic PCs. ;PBCre mice. Whole-body loss of both Spop alleles is incompatible with postnatal survival. 21 Thus, biallelic ablation of Spop requires the development of a prostate-specific KO. For that purpose, we crossed our Spop tm1a(KOMP)Wtsi mice with ROSA-Flp mice (with the Flippase gene knocked into the ROSA26 locus), in order to remove the LacZ and neomycin-resistance cassettes (Supplementary Figure 2) . In doing so, we generated Spop floxed alleles (Spop fl ), where Spop exons 4 and 5 (encoding the core of the MATH domain) are flanked by loxP sites. We then crossed our Spop fl/fl mice with a probasin (PB)-Cre transgenic mouse line 57 Transient transfection of expression vectors into mammalian cells 293T cells were transfected with expression vectors using Superfect transfection reagent (Qiagen, Germantown, MD, USA) following the manufacturer's instructions. Typically, for a six-well plate, 3 μg of DNA/ well was transfected; and for a 10-cm plate, 20 μg of DNA were utilized. Forty-eight hours post-transfection, the cells were harvested and washed with PBS. Total RNA or total cell lysates were prepared and used for RT-qPCR or immunoblot analyses as indicated.
Protein co-immunoprecipitation analysis
For determination of protein-protein interactions, 293T cells were cotransfected with FLAG-tagged c-Myc WT (or FLAG-tagged c-Myc ΔSBC1 or FLAG-tagged c-Myc ΔSBC2) and pcDNA3.1-HA-SPOPWT (or pcDNA3.1-HA-SPOPF102C or pcDNA3.1-HA-SPOPF133V) for 24 h. Subsequently, the cells were treated with bortezomib for 16 h, harvested and lysed in NP-40 lysis buffer containing protease inhibitor cocktail (Roche Applied Science). Anti-FLAG and anti-SPOP antibodies were utilized for the immunoprecipitation reactions. The immuno-complexes were isolated by magnetic protein G-Dynabeads (Life Technologies, Carlsbad, CA, USA), washed 4X with lysis buffer and eluted from the magnetic beads utilizing 1X SDS loading buffer and boiling the tubes at 100°C for 5 min. Proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes, and detected by immunoblotting for FLAG-c-Myc (mouse anti-FLAG-HRP), HA-tagged SPOP (rat anti-HA-HRP), and SPOP.
For protein-protein interactions, LNCaP cell were collected and lysed in NP-40 lysis buffer with protease inhibitor cocktails. Anti-SPOP antibody was used in co-immunoprecipitation analysis to precipitate SPOP-interacting protein complexes. The immuno-complexes were precipitated by protein G Dynabeads, washed, eluted, and separated by SDS-PAGE. SPOP and c-Myc protein were detected by immunoblotting as described below.
Immunoblot analyses
After SDS-PAGE, the proteins were transferred to nitrocellulose or lowfluorescent PVDF membrane and detected by immunoblotting using monoclonal antibodies or specific anti-sera, as indicated. Blots were washed with 1X PBST and incubated with anti-mouse or anti-rabbit HRPconjugated or IR-680 and IR-800 dye-conjugated secondary antibodies (LI-COR Biotechnology, Lincoln, NE, USA) for 1 h. Protein signals were detected with SuperSignal Western chemiluminescent substrate (Thermo Scientific) and developed with X-ray films according to the manufacturer's instructions (Thermo Scientific) or via infrared detection of immunoblots using a LI-COR Odyssey 3000 infrared imager. Densitometric analysis was conducted using NIH ImageJ image analysis software 58 or QuantityOne Software (Bio-Rad, Hercules, CA, USA).
In vivo (intracellular) ubiquitination assay
To examine intracellular ubiquitination of c-Myc that is specifically promoted by SPOP, Hela cells cultured in 10-cm plates were transiently co-transfected by 1.5 μg of plasmid pcDNA3.1-2xFLAG-cMyc, pcDNA3.1-2xFLAG-c-Myc STS187/188/189AAA (ΔSBC1) or pcDNA3.1-2xFLAG-c-Myc TSS263/264/265AAA (ΔSBC2), together with 1.5 μg each of protein expression vectors: pcDNA3.1-HA-SPOP (or pcDNA3.1-HA-SPOPF102C), pcDNA3-myc3-ROC1, pcDNA3-myc-CUL3 and pCI-His-hUbiquitin. Fortyeight hours after the transfection, the cells were incubated with 250 nM of bortezomib for another 6 h. The cells were collected and 1/10 of cells were lysed and sonicated in 1X RIPA buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na 3 VO 4 and 1 μg/ml leupeptin). The RIPA lysates were measured for protein concentration, serving as total protein input control. The remaining cells were lysed in U-Lysis Buffer (6 M Guanidine-HCl, 0.1 M Sodium Phosphate, pH 8.0 and 10 mM imidazole) and sonicated. Supernatants were incubated with 100 μL of nickel-nitrilotriacetic acid (Ni-NTA) agarose beads (Qiagen) at 4°C overnight. The Ni-NTA beads were washed with U-Lysis Buffer, Wash Buffer I (25 mM Tris-HCl, pH7.4, 150 mM NaCl and 15 mM imidazole),and Wash Buffer II (25 mM Tris-HCl, pH 6.8 and 20 mM imidazole). Finally, the proteins bound to the Ni-NTA agarose beads were eluted by boiling in 1X SDS loading buffer containing 500 mM imidazole, resolved by SDS-PAGE, transferred to NC membrane and detected by immunoblot analysis as described above.
Immunohistochemistry and immunofluorescence were performed as described previously 17, 59 respectively. RT-qPCR and bioinformatics analysis were performed as described previously. 6, 60, 61 Additional details for Materials and Methods, including primer sequences and prostate organoid assay, are available in the Supplement. All reviews of all IHC slides were performed by a board-certified pathologist and prostate cancer expert (M. I.). Due to the hypercellularity and larger size of the Spop KO prostates, it is practically impossible to truly blind these samples.
